Loading
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
Previous close
$37.01
−$0.59 · -1.57%
Regular session · ET · Market data may be delayed.
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
Day range
Current $37.01
52-week range
Current $37.01
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
45
Fair Value
Sentiment
49
Mixed
Risk
54
Elevated Risk
Momentum
70
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
Day range
Current $37.01
52-week range
Current $37.01
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 29.64M EUR | −7.19M EUR | 36.21M EUR | 4.78M EUR | 2.65M EUR |
| Gross profit | 29.64M EUR | −7.19M EUR | 36.21M EUR | 4.78M EUR | 2.65M EUR |
| Research and development | 23.12M EUR | 40.54M EUR | 38.4M EUR | 32.64M EUR | 30.38M EUR |
| Selling, general, and administrative | 20.22M EUR | 20.53M EUR | 22.05M EUR | 17.86M EUR | 19.43M EUR |
| Operating expenses | 40.46M EUR | 61.2M EUR | 62.99M EUR | 51.48M EUR | 55.23M EUR |
| Interest income | 985K EUR | 2.63M EUR | 1.22M EUR | 256K EUR | — |
| Interest expense | 10.4M EUR | 8.09M EUR | 7.98M EUR | 5.84M EUR | 699.49K EUR |
| Depreciation and amortization | 1.5M EUR | 592K EUR | 551K EUR | 1.5M EUR | 1.56M EUR |
| Operating income | −10.82M EUR | −68.39M EUR | −26.78M EUR | −46.7M EUR | −52.58M EUR |
| Net income | −23.96M EUR | −68.13M EUR | −39.7M EUR | −57.04M EUR | −47M EUR |
Company facts updated Sep 13, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$38.00
2.67% upsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
